Emgality® (Galcanezumab)

Para consultar la información para prescribir completa de Emgality® (Galcanezumab) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

What potential drug-drug interactions does galcanezumab have?

Drug interaction studies were not conducted. No pharmacokinetic drug interactions are expected based on the characteristics of galcanezumab.

MX_cFAQ_GLC075_POTENTIAL_DDI
MX_cFAQ_GLC075_POTENTIAL_DDI
es-MX

Additional Information Regarding Galcanezumab Drug Interactions

Pharmacokinetic Characteristics

Galcanezumab is an IgG4 monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.1,2

As such, it is not expected to

  • inhibit metabolic or induce enzymatic pathways
  • be metabolized by the cytochrome P450 families of drug-metabolizing enzymes, and
  • produce any active metabolites.1-3

Drug Interactions Studies Were Not Conducted

Based on the PK characteristics of galcanezumab, drug interactions are not expected. Therefore, no drug interaction studies were conducted.1

There are no known interactions for galcanezumab, drug-drug or otherwise.1

References

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780

3Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645-2668. https://doi.org/10.1002/jps.20178

Glossary

IgG = immunoglobulin G

IgG4 = immunoglobulin G (subclass) 4

PK = pharmacokinetics

Fecha de la última revisión: 2019 M06 10


Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta